Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Podofilox is a small molecule antimitotic drug used topically for the treatment of external genital and perianal warts (condyloma acuminatum). It is a purified form of podophyllotoxin, a lignan derived from the roots of Podophyllum species or synthesized chemically. Podofilox acts primarily by binding to tubulin, destabilizing microtubules, and thereby inhibiting cell division in wart tissue. This leads to cell death and removal of wart tissue. Some evidence also suggests it may modulate DNA topoisomerase II activity, but its main action is as a microtubule inhibitor. Podofilox is not curative for HPV infection but removes visible warts on external genital skin[1][3][5][7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on podofilox.